When ovarian cancer returns and treatment options become harder to choose, a novel lab test called the SAGE Oncotest may help guide a better-informed treatment decision. In contrast to other standard cancer diagnostics, this test evaluates how a live sample of your own tumor tissue actually responds to various treatment options. This test is designed to complement and go well beyond genomic testing alone, so that the most effective therapy can be selected. It is ordered by yo

SAGE Oncotest Reveal™ showed marked differences in ovarian cancer drug response using viable patient-derived 3D microtumors. Among 17 specimens, responses to NCCN-recommended therapies varied widely, especially for carboplatin/paclitaxel. Some tumors with reduced response to standard platinum-taxane therapy showed greater sensitivity to alternatives such as gemcitabine or doxorubicin.